Table 3.
Method | Stage of results chain | Purpose | Data sources | Example finding |
---|---|---|---|---|
Process tracking | All, except impact. | Monitored fidelity of programme activities and outputs against ToC to identify successes and challenges during programme implementation |
|
See the 2016 cross-country report for how years of process tracking was used to explain years of HSS grant implementation delays across FCE countries (Gavi Full Country Evaluations Team, 2017) |
RCA | All, except impact. |
Generates and tests hypotheses about the underlying causes of key programme success and challenges against all available evidence Synthesizes relevant evidence for developing key findings and recommendations |
Desk review, key informant and fact-checking interviews, analysis of HMIS data | See Figure 4 for an example related to the sub-optimal coverage of new vaccines in Mozambique |
Small-area estimates of vaccine coverage | Outcomes | Improve granularity of estimates of vaccine coverage in FCE countries to inform recommendations for resource targeting | Household surveys | Small-area estimates identified sub-national inequalities in each country |
Observational study of determinants and constraints of effective vaccine coverage (Phillips et al., 2018) | Outputs to outcomes | Identify determinants of effective vaccine coverage to inform recommendations for improvement |
|
See Phillips et al., 2018for estimates of the relative contribution of household and health systems determinants of the probability of a child being vaccinated |
Resource tracking | Inputs | Estimate national resource envelopes and sources |
|
Resource tracking results were reported in 2016 country reports and paved the way for further analyses of fiscal space and financing scenarios in 2017 |
Partnership/network analysis | Any (but primarily inputs to activities) | Evaluate the effectiveness, efficiency and country ownership of national immunization partnerships and their contribution programme performance |
|
We analysed the structure and composition of the Uganda HPV vaccine introduction partners’ network to explain successes and challenges observed during decision-making around HPV vaccine (Kamya et al., 2016) |
Vaccine effectiveness study | Impact | Estimate the impact of pneumococcal conjugate vaccine (PCV) |
|
Together, these studies provided strong evidence of the effectiveness and impact of PCV10 on nasopharyngeal carriage of vaccine-type pneumococcus and the incidence of vaccine-type invasive pneumococcal disease and pneumonia (Gavi Full Country Evaluations Team, 2017) |
Regression analyses | Impact | Estimate the impact of new vaccine introductions of PCV and rotavirus vaccines on child mortality |
|
Our analyses indicate that high coverage of new vaccines is associated with significant improvements in child mortality. In 2016, there were 10.1% (95% UI: 6.4, 13.8) and 11.9% (95% UI: 9.4, 14.3) reductions in under-5 mortality in Mozambique and Zambia, respectively, compared with scenarios where these vaccines were not introduced (Gavi Full Country Evaluations Team, 2017) |
District case studies (Phase 2) | Inputs to activities to outputs to outcomes | Identify the drivers of district performance |
|
District case studies identified barriers and enablers of vaccine coverage; see e.g. Uganda’s 2017–18 report (Gavi Full Country Evaluations Team, 2018) |